Entrada Therapeutics Inc
NASDAQ:TRDA
Intrinsic Value
Entrada Therapeutics, Inc. operates as a biotechnology company. [ Read More ]
The intrinsic value of one TRDA stock under the Base Case scenario is 6.6 USD. Compared to the current market price of 14.17 USD, Entrada Therapeutics Inc is Overvalued by 53%.
Valuation Backtest
Entrada Therapeutics Inc
Run backtest to discover the historical profit from buying and selling TRDA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Entrada Therapeutics Inc
Current Assets | 369.8m |
Cash & Short-Term Investments | 352m |
Receivables | 5.9m |
Other Current Assets | 11.9m |
Non-Current Assets | 99.4m |
PP&E | 92.7m |
Other Non-Current Assets | 6.7m |
Current Liabilities | 158.8m |
Accounts Payable | 3.3m |
Accrued Liabilities | 19.2m |
Other Current Liabilities | 136.3m |
Non-Current Liabilities | 68m |
Other Non-Current Liabilities | 68m |
Earnings Waterfall
Entrada Therapeutics Inc
Revenue
|
129m
USD
|
Operating Expenses
|
-132.2m
USD
|
Operating Income
|
-3.2m
USD
|
Other Expenses
|
-3.5m
USD
|
Net Income
|
-6.7m
USD
|
Free Cash Flow Analysis
Entrada Therapeutics Inc
What is Free Cash Flow?
TRDA Profitability Score
Profitability Due Diligence
Entrada Therapeutics Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Entrada Therapeutics Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
TRDA Solvency Score
Solvency Due Diligence
Entrada Therapeutics Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Score
Entrada Therapeutics Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TRDA Price Targets Summary
Entrada Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for TRDA is 21.42 USD with a low forecast of 20.2 USD and a high forecast of 23.1 USD.
Ownership
TRDA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
TRDA Price
Entrada Therapeutics Inc
Average Annual Return | -17.98% |
Standard Deviation of Annual Returns | 3.72% |
Max Drawdown | -84% |
Market Capitalization | 473.8m USD |
Shares Outstanding | 33 368 100 |
Percentage of Shares Shorted | 9.38% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Entrada Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 114 full-time employees. The company went IPO on 2021-10-29. The firm's EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its EEV Platform, Entrada is building a development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular diseases, immunology, oncology and diseases of the central nervous system. The firm's lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD), and a follow-on program targeting myotonic dystrophy type 1 (DM1). DMD is a monogenic X-linked disease caused by mutations in the DMD gene.
Contact
IPO
Employees
Officers
The intrinsic value of one TRDA stock under the Base Case scenario is 6.6 USD.
Compared to the current market price of 14.17 USD, Entrada Therapeutics Inc is Overvalued by 53%.